Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 October 2021Website:
http://minktherapeutics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 21:13:46 GMTDividend
Analysts recommendations
Institutional Ownership
INKT Latest News
MiNK Therapeutics, Inc. (INKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to unveil updated clinical and translational data, along with insights on agenT-797's distinct mechanism of action in solid tumors. A poster will be presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting on November 1-5, 2023.
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer and President, will participate in the following upcoming investor conferences:
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its virtual-only Annual Meeting of Shareholders will be held on Tuesday, June 13, 2023, at 10:30 AM ET.
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Zack Armen – Head-Investor Relations Jennifer Buell – President and Chief Executive Officer Marc Van Dijk – Chief Scientific Officer Christine Klaskin – Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar – H.C. Wainwright Jack Allen – Baird Matthew Phipps – William Blair Operator Ladies and gentlemen, thank you for standing by.
After losing some value lately, a hammer chart pattern has been formed for MiNK Therapeutics, Inc. (INKT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AgenT-797 data presented at SITC in November was encouraging. More AgenT-797 cancer data expected at AACR on April 18.
What type of business is MiNK Therapeutics?
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
What sector is MiNK Therapeutics in?
MiNK Therapeutics is in the Healthcare sector
What industry is MiNK Therapeutics in?
MiNK Therapeutics is in the Biotechnology industry
What country is MiNK Therapeutics from?
MiNK Therapeutics is headquartered in United States
When did MiNK Therapeutics go public?
MiNK Therapeutics initial public offering (IPO) was on 15 October 2021
What is MiNK Therapeutics website?
https://minktherapeutics.com
Is MiNK Therapeutics in the S&P 500?
No, MiNK Therapeutics is not included in the S&P 500 index
Is MiNK Therapeutics in the NASDAQ 100?
No, MiNK Therapeutics is not included in the NASDAQ 100 index
Is MiNK Therapeutics in the Dow Jones?
No, MiNK Therapeutics is not included in the Dow Jones index
When does MiNK Therapeutics report earnings?
The next expected earnings date for MiNK Therapeutics is 09 August 2024